-
Has your clinic telephone been ringing recently with calls from women who have heard about a birth control pill recall? Chances are, few, if any, of your patients were using the affected oral contraceptives (OCs).
-
New research indicates that the human papillomavirus vaccine (HPV) Gardasil (Merck & Co.) does not trigger autoimmune conditions such as lupus, rheumatoid arthritis, type 1 diabetes, or multiple sclerosis after vaccination in young women.
-
Results from a large, long-running Scandinavian study provides convincing evidence that combined oral contraceptives (OCs) alleviate the symptoms of dysmenorrhea, painful menstrual periods.
-
Ulipristal acetate, the drug recently approved as an emergency contraceptive in the United States (Ella, Watson Pharmaceuticals, Morristown, NJ), is being eyed for other gynecologic uses. In research looking at women with symptomatic fibroids who were planning to undergo surgery, treatment with the selective progesterone-receptor modulator was effective in controlling excessive bleeding and reducing fibroid size at 13 weeks.
-
Combination oral contraceptives (OCs) are the most common form of hormonal contraception used by sexually active females ages 15-19, with 56% of this group reporting ever having used OCs, and 30% reporting use at last intercourse.
-
While pills remain a popular birth control choice, more women are selecting long-acting reversible contraception (LARC), say respondents to the 2011 Contraceptive Technology Update Contraception Survey. More than 80% of respondents say they have seen an increase in LARC methods.
-
A woman comes into your office and says she wants to use an oral contraceptive (OC) for birth control. After confirming that she is a good candidate for the method, when do you start her on her first pack of pills?
-
While combined oral contraceptives (OCs) remain a leading choice for contraception, other methods are making their mark. About 38% of respondents to the 2011 Contraceptive Technology Update Contraception Survey said more than half of their patients use OCs, a drop from 2010's 42% level.
-
New labeling is being eyed regarding increased risks for blood clots for the contraceptive patch and combined oral contraceptives (COCs) containing the progestin drospirenone (DRSP) following recommendations from joint votes from two Food and Drug Administration (FDA) committees.
-
Almost 75% of respondents to the Contraceptive Technology Update 2011 Contraception Survey say they provide advance provision of emergency contraception (EC).
